Collaboration with Omega Pharma for SB12

Collaboration with Omega Pharma for SB12

 

Meda has signed a 5-year collaboration agreement with Omega Pharma for SB12 in
France, Italy, Belgium and Greece. Omega Pharma is a Belgian company with a
leading market position in the OTC segment in these countries.

SB12 is an oral care agent for bad breath. Meda has established SB12 as a market
leader in the Nordic region. In 2012, Meda intends to launch SB12 in about ten
markets across Europe under its own management.

"We continue to strengthen Meda’s future prospects in the OTC area", said Anders
Lönner, CEO of Meda AB.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46 709-458 878